Results 311 to 312 of about 369,175 (312)

[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study

Lancet, The
Simron Singh, Salvatore Tafuto, Secondo Lastoria   +2 more
exaly  

Mixed neuroendocrine-non-neuroendocrine neoplasms

La Rosa S, Milione M, Osamura RY, Rekhtman N, Tang LH, Uccella S   +5 more
openaire   +1 more source